Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Piperacillin Sodium

FDA-approved product (injectable, injection), marketed as Piperacillin, Pipracil.

Registered studies
50+
Lab records
245
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Piperacillin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Appendicitis
  • Bacterial disease
  • Cellulitis
  • Diabetic foot
  • Endometritis
  • Pelvic Inflammatory Disease
  • Peritonitis
  • Pneumonia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Penicillins with extended spectrum
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01CA12

Repurposing investigation

Piperacillin Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA92.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli16.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae28.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis42.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 6 of 12 lab records
  • E. coli: measured active in 10 of 42 lab records
  • K. pneumoniae: measured active in 30 of 191 lab records
Open Piperacillin Sodium in ChEMBL Registered studies below
Show the latest 150 of 245 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Piperacillin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Antimicrobial PK in Infants With Suspected or Confirmed Infection

    NCT00491426 · start 2006-01

    Registered record
    Registry ID
    NCT00491426
    Conditions
    Infection
    Interventions
    Ampicillin; Metronidazole; Piperacillin/Tazobactam; Acyclovir; Amphotericin B; Ambisome; Anidulafungin; Caspofungin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2006-01
    Completion
    2010-11
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection
    InterventionAmpicillin; Metronidazole; Piperacillin/Tazobactam; Acyclovir +4 more
    PhaseNot recorded
    Registry statusCompleted

  • Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses

    NCT00629135 · start 2005-11-15

    Registered record
    Registry ID
    NCT00629135
    Conditions
    Abscess, Intra-Abdominal
    Interventions
    Moxifloxacin/Metronidazole or Piperacillin/Tazobactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-11-15
    Completion
    2011-08-15
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAbscess, Intra-Abdominal
    InterventionMoxifloxacin/Metronidazole or Piperacillin/Tazobactam
    PhasePhase 3
    Registry statusCompleted

  • Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

    NCT00167999 · start 2005-02

    Registered record
    Registry ID
    NCT00167999
    Conditions
    Gram-Positive Bacterial Infections; Escherichia Coli Infections; Klebsiella Infections
    Interventions
    piperacillin-tazobactam
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2005-02
    Completion
    Not recorded
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGram-Positive Bacterial Infections; Escherichia Coli Infections; Klebsiella Infections
    Interventionpiperacillin-tazobactam
    PhaseNot recorded
    Registry statusCompleted

  • Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037)

    NCT00389987 · start 2001-09

    Registered record
    Registry ID
    NCT00389987
    Conditions
    Complicated Intra-Abdominal Infections
    Interventions
    MK0826, /Duration of Treatment : 8 Weeks; Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-09
    Completion
    2004-05
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Intra-Abdominal Infections
    InterventionMK0826, /Duration of Treatment : 8 Weeks; Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks
    PhasePhase 3
    Registry statusCompleted

  • Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients

    NCT00195533 · start 2001-07

    Registered record
    Registry ID
    NCT00195533
    Conditions
    Hematological Malignancy; Leukemia; Myelodysplasia; Lymphoma; Myeloma; Stem Cell Transplantation
    Interventions
    piperacillin-tazobactam; glycopeptide
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2001-07
    Completion
    2005-03
    Enrolment
    801

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematological Malignancy; Leukemia; Myelodysplasia; Lymphoma +2 more
    Interventionpiperacillin-tazobactam; glycopeptide
    PhaseNot recorded
    Registry statusCompleted